Clinical trials: Pituitary
Pituitary Tumor, Endocrine Neoplasia
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
The study aims to update current knowledge about the epidemiology of pituitary tumours (PiT), based on the wide body of scientific literature on new familial and/or syndromic forms.
- Conditions
- Pituitary Tumor, Endocrine Neoplasia, Hyperparathyroidism, Solid Tumor
- Trial name
- EpidemioPIT (NCT03973450)
- Testing
- Registration of familial forms and associated neoplasia
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Neuromed IRCCS
Pituitary Tumor, Optic Chiasm Disorder
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression.
- Trial name
- RetroADEN (NCT03363126)
- Testing
- Endonasal transsphenoidal pituitary tumor removal
- Volunteers
- 88 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Myocardial Infarction
Accelerated Rule Out of Myocardial Infarction
Every year > 50.000 people in Denmark are hospitalized with a suspected acute myocardial infarction (AMI). The majority has other explanations of their chest discomfort and most are discharged again without any initiation of…
- Trial name
- AROMI (NCT02666326)
- Testing
- Accelerated, combined biomarker rule-out strategy for MI
- Where
- 3 sites in Denmark
- Volunteers
- 4,516 people
- Sponsor
- Aarhus University Hospital Skejby
Overweight and Obesity, Metabolic Syndrome
Changes in the Hypotalamic-pituitary Region of Patients With Metabolic Syndrome and Obesity
This study aims to identify new morphological and quantitative magnetic imaging parameters of pituitary gland and sellar region in overweight and obese patient at baseline and after 3 years, dividing patients in 3 groups (weight…
- Trial name
- CHIASM (NCT03458533)
- Testing
- Bariatric surgery, Diet and lifestyle changes
- Where
- Italy
- Volunteers
- 69 people
- Sponsor
- University of Roma La Sapienza
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Acromegaly
Non Interventional Post Marketing Programme in Acromegaly
The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group") and the safety and local tolerability…
- Trial name
- NCT00747500
- Where
- 7 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Ipsen
Osteoporosis, Hypercalcemia
Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders
Hormones are chemical messengers that help regulate many functions in the body. As women go through menopause, and as men age, levels of certain reproductive hormones change significantly.
- Conditions
- Osteoporosis, Hypercalcemia, Primary Hyperparathyroidism, Adrenal Gland Disease
- Trial name
- NCT07824102
- Where
- Denmark
- Volunteers
- 20,000 people
- Sponsor
- Martin Blomberg Jensen
Adult Growth Hormone Deficiency, Growth Hormone Disorder
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily Norditropin® FlexPro® (somatropin delivered…
- Trial name
- REAL 2 (NCT02382939)
- Testing
- somapacitan, somatropin
- Where
- 28 sites in Denmark, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Novo Nordisk A/S
Acromegaly Due to Pituitary Adenoma
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
In this study, the investigators hypothesize that upfront gamma knife radiosurgery with drug therapy is superior in the treatment of growth hormone-secreting pituitary tumors after primary surgical treatment compared with the…
- Trial name
- MERGE (NCT03439709)
- Testing
- Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Samsung Medical Center
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Growth Hormone Deficiency
A Study of Zomacton in Children With Growth Hormone Deficiency
This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year.
- Trial name
- NCT00884000
- Testing
- Genotropin, Zomacton
- Where
- 43 sites in Hungary, India and 5 more
- Volunteers
- 165 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Deficiency (GHD)
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis.
- Trial name
- NCT01947907
- Testing
- ACP-001, Human Growth Hormone
- Where
- 36 sites in Belarus, Bulgaria and 12 more
- Volunteers
- 53 people
- Sponsor
- Ascendis Pharma A/S
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Pituitary Adenoma, Adrenal Insufficiency
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.
- Conditions
- Pituitary Adenoma, Adrenal Insufficiency, Surgery
- Trial name
- NCT04621565
- Testing
- Normal saline, Hydrocortisone
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Peking Union Medical College Hospital
Wolfram Syndrome
Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome
Open label, phase II study non randomized single group assignment of 20 evaluable patients 13 years and older, over 37,5 kg body-weight, with sensorineural hearing loss of at least 20 dB at 8 kHz in high frequency average (HFA)…
- Trial name
- AUDIOWOLF (NCT04940572)
- Testing
- Depakine
- Where
- 2 sites in France, Spain
- Volunteers
- 23 people
- Sponsor
- Centre d'Etude des Cellules Souches
Acromegaly
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma.
- Trial name
- NCT00171730
- Testing
- Pasireotide
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
The Effect of Semaglutide on Pituitary Function
The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.
- Trial name
- NCT04865744
- Testing
- Semaglutide 7 MG Oral Tablet, Semaglutide 14 MG Oral Tablet
- Where
- Estonia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Tartu
Brain Neoplasm, Glioblastoma
Evaluation of Factors in Human Brain Tumors
Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy).
- Conditions
- Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
- Trial name
- NCT00001171
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Acromegaly
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control.
- Trial name
- STOP-SST (NCT05149495)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Growth Hormone Deficiency
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
- Trial name
- NCT00684957
- Testing
- Recombinant Human Growth Hormone, Recombinant Human IGF-1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University